Original language | English |
---|---|
Pages (from-to) | 26-29 |
Number of pages | 4 |
Journal | Schizophrenia Research |
Volume | 246 |
DOIs | |
Publication status | Published - Aug 2022 |
Keywords
- 25-hydroxyvitamin D (25(OH)D)
- Cardiovascular
- First episode psychosis
- Lipids
- Schizophrenia
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Schizophrenia Research, Vol. 246, 08.2022, p. 26-29.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Vitamin D and cardiometabolic outcomes in first episode psychosis (FEP)
T2 - A prospective cohort study
AU - Lally, John
AU - Ajnakina, Olesya
AU - Stubbs, Brendon
AU - Gardner-Sood, Poonam
AU - Di Forti, Marta
AU - Smith, Shubulade
AU - Howes, Oliver
AU - Gaughran, Fiona
N1 - Funding Information: O.A. is funded by the National Institute for Health Research (NIHR) (NIHR Post-Doctoral Fellowship - PDF-2018-11-ST2-020 ). BS is supported by a Clinical Lectureship ( ICA-CL-2017-03-001 ) jointly funded by Health Education England (HEE) and the National Institute for Health Research (NIHR). BS is part funded by the NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust . BS holds active grants with the Medical Research Council and Guys and St Thomas Charity ( GSTT ). FG is in part supported by the National Institute for Health Research's (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London , the Maudsley Charity and the National Institute for Health Research (NIHR) Applied Research Collaboration South London (NIHR ARC South London) at King's College Hospital NHS Foundation Trust. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care. Funding Information: This paper summarises independent research funded by the National Institute for Health Research (NIHR) under its IMPACT Programme (Grant Reference Number RP-PG- 0606-1049 ) and had support from the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London . Funding Information: OH has received investigator-initiated research funding from and/or participated in advisory/speaker meetings organised by. Astra-Zeneca, Autifony, BMS, Eli Lilly,. Heptares, Jansenn, Lundbeck, Lyden-Delta,. Otsuka, Servier, Sunovion, Rand and Roche.
PY - 2022/8
Y1 - 2022/8
KW - 25-hydroxyvitamin D (25(OH)D)
KW - Cardiovascular
KW - First episode psychosis
KW - Lipids
KW - Schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=85132228370&partnerID=8YFLogxK
U2 - 10.1016/j.schres.2022.05.019
DO - 10.1016/j.schres.2022.05.019
M3 - Article
AN - SCOPUS:85132228370
SN - 0920-9964
VL - 246
SP - 26
EP - 29
JO - Schizophrenia Research
JF - Schizophrenia Research
ER -